Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has shared an announcement.
Kindstar Globalgene reported 2025 revenue of RMB933.6 million, up 0.65% year on year, as it navigated industry-wide adjustment in China’s third-party medical testing sector amid tighter medical insurance cost controls and increased mutual recognition of lab results. The group maintained its “Specialty Esoteric Testing + Precision Medicine” strategy, leveraging hematology as a core business while using acquisitions to enter the early screening market for solid tumors and accelerating the build-out of its research and CRO offerings.
Gross profit fell 6.53% to RMB410.9 million and gross margin slid to 44.0% from 47.4%, reflecting ramp-up costs from new units, transitional expenses from internal restructuring and pricing pressure at the end market. Net loss narrowed to RMB55.1 million, helped by cost-efficiency measures and higher fair value gains on investments, although these benefits were partly offset by added credit-loss provisions and strategic spending tied to the AnchorDx acquisitions and CRO expansion.
The board also unveiled guidelines for final dividend distribution for 2025 to 2027, signaling an intent to provide clearer return expectations to shareholders as the company invests in new growth segments. In parallel, Kindstar announced board appointments and proposed the adoption of a twelfth amended and restated memorandum and articles of association, moves that underscore ongoing adjustments to its governance framework as it adapts to regulatory and market shifts.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. is a Cayman Islands-incorporated provider of third-party medical testing services, with a strategic focus on specialty esoteric testing and precision medicine. The group has core strengths in hematology testing and is expanding into early screening for solid tumors and scientific research and CRO services to capture growth areas in China’s evolving diagnostics market.
Average Trading Volume: 591,904
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.14B
For detailed information about 9960 stock, go to TipRanks’ Stock Analysis page.